Terms: = Lung cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Prognosis
34 results:
1. Impact of Histone Lysine Methyltransferase SUV4-20H2 on cancer Onset and Progression with Therapeutic Potential.
Papadaki S; Piperi C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473745
[TBL] [Abstract] [Full Text] [Related]
2. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
3. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.
Tan J; Yu Y; Lin X; He Y; Jin W; Qian H; Li Y; Xu X; Zhao Y; Ning J; Zhang Z; Chen J; Wu X
Hepatol Int; 2024 Apr; 18(2):550-567. PubMed ID: 37067674
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell lung cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract] [Full Text] [Related]
5. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract] [Full Text] [Related]
6. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
7. A novel function of HRP-3 in regulating cell cycle progression via the HDAC-E2F1-Cyclin E pathway in lung cancer.
Yun HS; Lee J; Kim JY; Sim YJ; Lee CW; Park JK; Kim JS; Ahn J; Song JY; Baek JH; Hwang SG
Cancer Sci; 2022 Jan; 113(1):145-155. PubMed ID: 34714604
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA-99a-3p/GRP94 axis affects metastatic progression of human papillary thyroid carcinoma by regulating ITGA2 expression and localization.
Gao Y; Pan Y; Wang T; Yao Y; Yuan W; Zhu X; Wang K
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1650-1661. PubMed ID: 34687203
[TBL] [Abstract] [Full Text] [Related]
9. The significance of immune-regulatory molecule B7-H4 in small cell lung cancer.
Zhang X; Song S; Zhang F; Cai L; Xie W
Ann Palliat Med; 2020 Jul; 9(4):1953-1957. PubMed ID: 32692215
[TBL] [Abstract] [Full Text] [Related]
10. Unique Genetic Characteristics and Clinical prognosis of Female Patients with lung cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract] [Full Text] [Related]
11. The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer.
Yuan L; Ye J; Fan D
Hum Immunol; 2020 May; 81(5):254-261. PubMed ID: 32113654
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptional profiling of long-intergenic noncoding RNAs in lung squamous cell carcinoma and its value in diagnosis and prognosis.
Liu J; Yao Y; Hu Z; Zhou H; Zhong M
Mol Genet Genomic Med; 2019 Dec; 7(12):e994. PubMed ID: 31617686
[TBL] [Abstract] [Full Text] [Related]
13. Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis.
Chiou J; Chang YC; Jan YH; Tsai HF; Yang CJ; Huang MS; Yu YL; Hsiao M
Sci Rep; 2019 Oct; 9(1):14624. PubMed ID: 31601833
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of ccdc6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract] [Full Text] [Related]
15. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
[TBL] [Abstract] [Full Text] [Related]
16. [Research progress in the role of FBXW7 in drug resistance against non-small cell lung cancer].
Peng Z; Chen Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Apr; 44(4):444-448. PubMed ID: 31113922
[TBL] [Abstract] [Full Text] [Related]
17. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell lung Carcinoma Tumors.
Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists.
Chen C; Qu QX; Xie F; Zhu WD; Zhu YH; Huang JA
BMC Cancer; 2017 Sep; 17(1):652. PubMed ID: 28923053
[TBL] [Abstract] [Full Text] [Related]
20. The HRH4 rs11662595 mutation is associated with histamine H
Cai WK; Zhang JB; Chen JH; Meng JR; Ma X; Zhang J; Zhou YL; Xu GL; He GH
Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2954-2963. PubMed ID: 28847511
[TBL] [Abstract] [Full Text] [Related]
[Next]
